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Figure 3a a biological sample is provided. The method detects a marker for infection by
providing a device, the device including a biosensor, an interaction arising be
tween the biosensor and the marker when the marker is present in the biological
sample. Contacting at least a part of the biological sample with the biosensor of
(a) *** the device, therefore, provides analysis of the biological sample with respect to
the marker by detecting for the interaction between the biosensor and the marker.










METHOD OF DETECTING BACTERIAL INFECTION IN A BIOLOGICAL SAMPLE
This invention concerns improvements in and relating t o detection, particularly of
the presence of a disease and/or of infection at a site, and/or improvements in and relating
t o transportation, particularly the transportation of pharmaceutical compounds to a site of
disease and/or infection.
There are many situations where detection of infection is a significant issue. In some
circumstances, the primary injury to the human body (for example a burn injury) itself
causes symptoms that mimic infection. The practice of microbiological swabbing, and
subsequent identification of organisms confirms their presence in a wound, but not the
presence of infection. Multi-drug resistance is a clinical concern, and administering
antibiotics where there might be no clinical need increases costs, and increases the well-
known risks from over use of antibiotics.
EP0145398 provides one form of sensor for the detection of amylase activity for the
purpose of revealing a disease which causes enhanced levels of amylase. There is no
suggestion that amylase (or closely related species) is indicative of infection and so no
suggestion that the detection of amylase provides for the detection of infection. The
approach is limited merely t o the revealing of one or a limited number of specific diseases.
GB2426335 relates to the detection of wound infection, but through the detection of
reactive oxygen species. These are unrelated t o amylase and so there no suggestion that
amylase is indicative of infection and so no suggestion that the detection of amylase
provides for the detection of infection.
US2012/0309036, W097/29366, US2015/0004627 and WO2010/124270 all provide
different types of sensors. None is for the detection of amylase and none provides that
amylase is indicative of infection and so no suggestion that the detection of amylase
provides for the detection of infection exists.
Approaches that do detect for bacterial infection, through very different
mechanisms t o the present invention, often determine the presence of bacteria and not
whether the bacteria are causing infection. The present invention has amongst its
potential aims to provide an improved method of analysis for a biomarker indicative of
infection, particularly bacterial infection. The present invention has amongst its potential
aims t o provide an improved method for detection of infection, particularly bacterial
infection. The present invention has amongst its potential aims an improved method for
indicating the presence of infection t o cause further investigations and/or further evaluation
before making a clinical diagnosis and/or proposing a treatment. The present invention has
amongst its potential aims to provide an improved method of analysis for a biomarker
indicative of infection, particularly bacterial infection.
The present invention has amongst its potential aims t o provide an improved
composition for pharmaceutical use. The present invention has amongst its potential aims
t o provide an improved composition for the targeted delivery of a composition for
pharmaceutical use.
According t o a first aspect the invention provides a method of analysing a biological
sample for a marker, the method comprising:
providing a device, the device including a sensor for the marker;
contacting at least a part of the biological sample with the device;
analysing the at least a part of the biological sample with respect t o the marker;
indicating a characteristic of the marker using the device;
wherein the biomarker is an enzyme, preferably amylase.
The first aspect of the invention may further include that:
the method of analysing is a method of indicating the presence of infection in
the biological sample; and/or
the method may include the sensor being a biosensor; and/or
the method may include an interaction arising between the sensor and the
marker when the marker is present in the biological sample; and/or
the method may further include contacting the at least a part of the
biological sample with the biosensor of the device; and/or
the method may further include detecting for the interaction between the
biosensor and the marker;
the method may further include the characteristic being the presence or
absence of the marker.
According t o a second aspect the invention provides a method of indicating the
presence of infection in a biological sample by investigating a marker for infection, the
method comprising:
providing a device, the device including a biosensor, an interaction arising between
the biosensor and the marker when the marker is present in the biological sample;
contacting at least a part of the biological sample with the biosensor of the device;
analysing the at least a part of the biological sample with respect t o the marker by
detecting for the interaction between the biosensor and the marker;
indicating a characteristic of the marker using the device, the characteristic being the
presence or absence of the marker;
wherein the marker is an enzyme, preferably amylase.
The first and second aspects of the invention may include any of the following
features, options or possibilities.
The method of analysing may be a method of diagnosis for infection.
The method of analysing may be a method of analysing for and/or detecting for
and/or diagnosing elevated marker levels at a site, for instance elevated levels compared
with an experimentally obtained baseline. The method of analysing may be a method of
analysing for and/or detecting for and/or diagnosing elevated marker levels at a site, for
instance elevated levels compared with an experimentally obtained baseline, arising from
infection at a site. The method of analysing may be a method of analysing for and/or
detecting for and/or diagnosing elevated marker levels at a site, for instance elevated levels
compared with marker levels at another location of the same patient, such as the blood. The
method of analysing may be a method of analysing for and/or detecting for and/or
diagnosing elevated marker levels at a site, for instance elevated levels compared with
marker levels at another location of the same patient, such as the blood, the elevated level
arising from infection at a site.
The method of analysing may be a method of quantifying the amount of the marker
in the at least a part of the biological sample. The method may quantify the activity of the
marker. The method may quantify the concentration of the marker. The method may
quantify the activity of the marker relative to the activity of the marker in a reference
sample. The method may quantify the concentration of the marker relative t o the
concentration of the marker in at least a part of a reference sample.
The reference sample may be another biological sample taken from the same
source, for instance the same human or animal. The reference sample is preferable taken
from another site on the source to the site being analysed, for instance for infection. The
other site may be a vein. The reference same may be a biological sample in which the
presence or amount of the marker is not influenced by the presence of infection at the site
being analysed. The reference sample may be an intravascular fluid, such as whole blood or
any of the separated components of blood, for example serum or plasma. One or more of
the separated components may be considered.
The biological sample may be body fluids and/or cells and/or processed cells and/or
a tissue sample taken from the site t o be analysed. The biological sample may be extracted
from an item which has been in proximity with the site t o be analysed, such as a dressing,
pad, compress, swab, skin substitutes, biomembrane. The biological sample may be taken
from inside and/or outside the body.
The site may by on the exterior of a body and/or the site may be interior to a body.
The site may be a surgical site, including a plastic surgery site. The site may be a disease site
and/or a pathology site. The site may be an infection site. The site may be an injury site. The
site may be a wound, for instance an open wound such as a tear, cut, puncture, incision,
laceration, abrasion, avulsion, penetration or gunshot wound or for instance a closed wound
such as a contusion, hematoma or crush injury. The site may particularly be a burn. The site
may be superficial or it may be deep, and in any layer, tissue, organ or bodily fluid.
The infection may be a bacterial infection. A bacterial infection may be defined as a
proliferation of bacteria on or inside a human or animal which causes harm t o the human or
animal. The bacterial infection may be homogeneous or heterogeneous. The bacterial
infection may be localised to one or more sites or systemic. The bacterial infection may be
symptomatic or asymptomatic.
Preferably the method is distinguishing for bacterial infection.
Preferably the method is distinguishing between bacterial infection and
inflammation.
The method may provide sensitivity to bacterial infection. The sensitivity may be
greater than 80%, preferably greater than 85%, more preferably greater than 90% and
ideally 98% or more.
The method may provide specificity with respect to the absence of bacterial
infection. The specificity may be greater than 75%, preferably greater than 80%, more
preferably greater than 85% and ideally 90% or more.
The infection may be caused by Gram positive (such as Straphyococus spp.) and/or
Gram negative organsims (such as Acinetobacter spp.). The infection may be caused aerobic
and/or micro-aerobic organisms (such as Streptocuccus sp.) and/or anaerobic organisms
(such as Clostridium spp.). The infection may be mono-microbial or poly-microbial. The
infection may be a poly-microbail infection which is synergistic or non-synergistic. The
infection may be one or more of: Steptococci, such as Streptococcus pyrogenesi, and/or
Enterococci, such as Enterococcus faecalis, and/or Staphylococci, such as Staphyloccoccus
aureus, and/or Psuedomonas, such as Pseudomonas aeruginosa, Enterobacter, Escherichia
coli, Klebsiella, Bacillus, such as B. cerus, Clostridium, such as C. perfringens, C. teanii, C.
difficile, Proteus, Bacteroides, Clostridium.
The marker is preferably an enzyme which is a catalyst for the hydrolysis of starch
into sugars. The marker may be a glycoside hydrolase. The marker is most preferably
amylase. The marker may be one or more or all of a mixture of enzymes. The marker is
preferably produced by the human or animal from which the biological sample is obtained.
The marker is preferably an enzyme which is a catalyst for the hydrolysis of starch into
sugars produced by the human or animal from which the biological sample is obtained. The
marker may be a glycoside hydrolase preferably produced by the human or animal from
which the biological sample is obtained. The marker is most preferably amylase preferably
produced by the human or animal from which the biological sample is obtained. The marker
may be one or more or all of a mixture of enzymes preferably produced by the human or
animal from which the biological sample is obtained.
The device may have a separate existence outside of the limitations of the method
and purpose of the method.
The device may include the sensor together with one or more or all of, a power
source, control electronics, a computer processor, computer memory, a user interface, a
user viewable display, a signal output connection, a signal input connection.
The device is preferably a self-contained unit. The device is preferably portable. The
device may be hand-held and/or desk-top.
The sensor may be screen printed on to a part of the device and/or a sensor support.
The sensor may detect the marker without the use of labels for the marker. The sensor may
be an immunosensor. The sensor is preferably a graphene based sensor.
The sensor may include an aromatic amine, such as aniline, on a support. The support
may be a graphene support, gold support, zinc oxide support, iron oxide support or other
forms of carbon support. Electropolymerisation of the aromatic amine, such as aniline, onto
the sensor support is preferred, for instance to achieve increased sensitivity and/or lower
limits of quantification. The sensor may be constructed by in situ electropolymerization of the
aromatic amine, such as aniline, onto a graphene support.
The sensor may include an enzyme antibody, preferably an enzyme specific antibody.
The sensor may include a glycoside hydrolase antibody, preferably a glycoside hydrolase
specific antibody. The sensor may include an amylase antibody, preferably an amylase specific
antibody. Preferably the sensor includes an a-amylase antibody, most preferably an a-
amylase specific antibody.
The sensor may be constructed by covalently binding the enzyme specific antibody t o
a layer. The layer may be a transducer layer. The layer may be a conductive polymer layer,
such as a polyaniline layer.
The transducer layer may be separate from a control electronics layer, may be
integrated there with or may be the same layer. The control electronics layer may be a
controlling device assembly.
The control electronics, such as a controlling device assembly, may use
electrochemical impedance spectroscopy t o analyse for and/or detect for and/or indicate the
marker. The control electronics, such as a controlling device assembly, may use variation in
the dielectric properties of the at least a part of the sample and/or the sensor as a function
of frequency.
The detecting for the interaction may use electrochemical impedance spectroscopy.
The detection for the interaction may use variation in the dielectric properties of the at least
a part of the sample and/or the sensor as a function of frequency. The sensor differs from
previous electrochemical impedance spectroscopy based sensors by using
electropolymerization in the construction of the sensor and/or in terms of the sensor being
used to determine the presence of bacterial infection through the detection of amylase.
Preferably the electrochemical impedance spectroscopy has a linear response against
a-amylase concentration. A linear response may be considered t o be a response which
deviates no more than 10% from linear.
Preferably electrochemical impedance spectroscopy generates a signal output when
the marker is present in the at least part of the sample. Preferably the signal output varies
with activity of the marker and/or concentration of the marker, ideally in a linear response.
The sensor may detect concentrations of the marker, preferably in a simulated
biological sample, biological sample or human plasma, as low as 100 International Units/L
(IU/L), preferably as low as 50 International Units/L (IU/L), more preferably as low as 10
International Units/L (IU/L), and ideally as low as International Units/L (IU/L). The sensor may
have a limit of detection as low as 1 U/L, preferably as low as 0.4 U/L, more preferably as low
as 0.1 U/L and ideally as low as 0.025 U/L and possibly even as low as 0.01 U/L.
The sensor may display a linear response to increasing a-amylase concentration
between 1 and 1000 International Units/L (IU/L), and/or a limit of detection of 0.025 U/L and
possibly even as low as 0.01 U/L.
The contacting of the at least a part of the sample with the sensor may be provided
by placing the sample on the sensor and/or dipping the sensor in the sample and/or
inserting the sample into the device.
The characteristic may be the presence of the marker. The characteristic may be the
absence of the marker. The characteristic may be the level of the marker, for instance
absolutely and/or relative to one or more predetermined thresholds. The characteristic may
be the quantity of the marker. The quantity of the marker may be the activity of the marker
and/or the concentration of the marker.
The characteristic may be the level of the marker in a sample taken from one type of
site compared with the level of the marker in a sample taken from another type of site. The
characteristic may be the difference between the level of the marker in a sample taken from
one type of site compared with the level of the marker in a sample taken from another type
of site. The characteristic may be the quotient of the level of the marker in a sample taken
from one type of site to the level of the marker in a sample taken from another type of site
and/or vice versa.
The characteristic may be expressed in terms of activity and/or concentration of the
marker.
The one type of site may be the infection site or potential infection site. The another
type of site may be a site distal from the one type of site in the same patient. The another
type of site may be a blood or plasma source. The another type of site may be associated
with the same patient as the one type of site, but the another type of site may be from a
control or reference individual or group of individuals.
The characteristic may be outputted from the device. The output may be a visual
display t o the user. The output may be an electronic signal and/or electrochemical signal.
The output may be a permanent recording of the characteristic.
The method of analysis may include a method for detecting the presence of
infection. The method of analysing may include a method of detecting the type of infection.
The type of infection may be with respect t o a classification of the source of infection, for
instance Gram negative or Gram positive. The type of infection may be with respect t o the
classification of the source of the infection, for instance bacterial, most preferably bacterial
only, with possibilities for viral, fungal, protazoal. The type of infection may be with respect
to the characterisation of the genus of the source of the infection, for instance one or more
selected from the group: Steptococci, Enterococci, Staphylococci, Psuedomonas,
Enterobacter, Klebsiella, Bacillus, Clostridium. The type of infection may be with respect to
the characterisation of the species of the source of the infection, for instance one or more
selected from the group: Streptococcus pyrogenesi, Enterococcus faecalis, Staphyloccoccus
aureus, Pseudomonas aeruginosa, Escherichia coli, Bacillus cerus, Clostridium perfringens,
Clostridium teanii, Clostridium difficile.
The method may be a method of verifying that the marker is present at a site, such
that the marker can activate a pharmaceutical compound when the pharmaceutical
compound is present at the site. The method may include a method of predicting and/or
estimating the activation rate of a pharmaceutical compound at a site by the marker. This is
a useful addition t o situations in which an inactive form may convert to the active form
because the marker, for instance amylase, causes the active compound to be rendered
pharmaceutically active, for instance by causing breakdown of the inactive form.
The method may be a method of investigating a site to establish that the marker is
preferentially present at the site, such that transportation of a pharmaceutical compound as
part of a combination with the marker, such as amylase, t o the site occurs.
According to a third aspect the invention provides a composition comprising a
pharmaceutical compound combined with a carrier constituent, the carrier constituent
comprising amylase.
According t o a fourth aspect the invention provides a composition comprising a
pharmaceutical compound combined with a carrier constituent, the carrier constituent
comprising an enzyme.
The enzyme is preferably a catalyst for the hydrolysis of starch into sugars. The
enzyme may be a glycoside hydrolase. Most preferably the enzyme is amylase. A mixture of
enzymes may be provided.
According to a fifth aspect of the invention there is provided a method of treatment
comprising administering to a human or animal of a composition comprising a
pharmaceutical compound combined with a carrier constituent, the carrier constituent
comprising amylase.
The method of treatment may be a method of treating infection and/or preventing
infection. The method of treatment may be for a human or animal with burns.
The third and/or fourth and/or fifth aspects of the invention may include any of the
following features, options and possibilities.
The pharmaceutical compound may be a pharmaceutically active compound. The
pharmaceutical compound may be pharmaceutically active compound whilst combined with
the carrier constituent. The pharmaceutical compound may be pharmaceutically active
compound after being separated from the carrier constituent. The pharmaceutical
compound may be a pharmaceutically in-active compound. The pharmaceutical compound
may transition from being a pharmaceutically in-active compound to a pharmaceutically
active compound due to an event. The event may be the passage of time and/or becoming
separated from the carrier constituent and/or interaction with another compound.
The pharmaceutical compound may be combined reversibly. The pharmaceutical
compound may be combined irreversibly.
The pharmaceutical compound may be combined with the carrier constituent, by
being combined directly with the amylase. The pharmaceutical compound may be combined
directly with the amylase by linking the pharmaceutical compound with the amylase. The
linking may be covalent linking. The linking may be cross-linking. The linking may be covalent
binding. The linking maybe ionic binding.
The pharmaceutical compound may be combined with the carrier constituent, by
being combined directly with an intermediary. The combination of the pharmaceutical
compound with the intermediate may be irreversible or reversible. The intermediary may be
combined directly with the amylase. The pharmaceutical compound may be combined
directly with the intermediary and/or the intermediary may be combined directly with the
amylase by linking. The linking may be the same or different with respect to the two links.
The linking may be covalent linking. The linking may be cross-linking. The linking may be
covalent binding. The linking maybe ionic binding.
The combination of the pharmaceutical compound with the carrier constituent may
be irreversible or reversible. The pharmaceutical compound can preferably be released from
the combination with the carrier constituent. The pharmaceutical compound may be
inactive or the activity may be impaired or inhibited when in combination with the carrier
constituent. Preferably the pharmaceutical compound is not impaired or inhibited in its
activity when released from the combination with the carrier constituent and/or when the
linking is reversed.
The intermediary may be a cross-linking compound. The pharmaceutical compound
may be bound directly t o amylase. This can be provided by a variety of mechanisms
including but not only, zero-length cross linking. The pharmaceutical compound may be
bound t o an intermediary which is then itself bound to amylase. The intermediary may be
non-biodegradable, for example poly(ethylene) glycol, or may be biodegradable.
The pharmaceutical compound may treat or prevent infection, particularly bacterial
infection. The pharmaceutical compound may treat or prevent infection by, amongst others,
Steptococci, such as Streptococcus pyrogenesi, and/or Enterococci, such as Enterococcus
faecalis, and/or Staphylococci, such as Staphyloccoccus aureus, and/or Psuedomonas, such
as Pseudomonas aeruginosa, Enterobacter, Escherichia coli, Klebsiella, Bacillus, such as B.
cerus, Clostridium, such as C. perfringens, C. teanii, C. difficile, Proteus, Bacteroides,
Clostridium.
The pharmaceutical compound may one or more of, including combinations of:
antibiotics, analgesics, opioids, anti-inflammatories, antihistamines.
The pharmaceutical compound may be used t o deliver therapy in multiple
modalities, alone or in combination.
The pharmaceutical compounds may include targeted pharmacotherapy and/or
targeted radiologically active compounds and/or compounds activated by light,
chromophores, and/or compounds activated by sound, such as ultrasound. The
pharmaceutical compound may include compounds acting through emission or through
their response t o emissions, as opposed t o just a pharmaceutical chemical interaction.
One or more different pharmaceutical compounds may be provided in the
composition.
The composition may be a parenteral administered composition, for instance for
injection, including sub-cutaneous, intramuscular, intravenous, intra-arterial, intrathecal,
intra-peritoneal injection. The composition may be an enteral administered composition, for
instance for oral administration. The composition may be provided in a medicinal product.
The medicinal product is preferably altered in the patient t o present the composition
in an absorbable form. For instance, the medicinal product may disintegrate during
ingestion and/or in the stomach and/or in the intestine to present the composition in an
absorbable form. The composition in the absorbable form preferably still comprises the
pharmaceutical compound combined with a carrier constituent, the carrier constituent
comprising amylase.
The composition in the absorbable form, preferably still comprising the
pharmaceutical compound combined with a carrier constituent, the carrier constituent
comprising amylase, preferably remains in the combined form for a time period which
provides for a proportion of the combined form to be transported t o the site t o be treated.
The proportion of the composition which remains in the combined form may be at least
25% of the total composition after the time period. The proportion is more preferably
greater than 40%, for instance greater than 50% of even greater than 70%. The time period
may be defined as the time of the peak concentration point at the site being treated. The
time period may be defined as at least 2 hours after administration.
Particularly when administered orally, the composition in the combined form is
provided with protection from being broken down by amylase and/or other intestinal
enzymes and conditions. The protection may be provided by providing linking which is not
susceptible to being broken by amylase and/or other intestinal enzymes and conditions.
The composition, particularly as a medicinal product, may be provided in one of the
following forms: tablets, capsules, powders, granules, microspheres or ointments, creams,
foams, solutions, suppositories, injections, lotions and aerosols.
The composition, particularly as a medicinal product, may be provided with one or
more excipients, diluents or adjuvants. For instance, one or more fillers, glidants, binders,
lubricants, anti-adherents, disintegrants, buffering agents, moisturising agents,
preservatives, solvents, solubilising agents, stabilizers.
Various embodiments of the invention will now be described, by way of example
only and with reference to the accompanying drawings in which:
Figure 1 shows a distribution graph illustrating that detection according to the
invention was useful across different types of bacteria, different types of wound, wound
dressing, antibiotics, wound site, and depth;
Figure 2 illustrates experimental results showing the amylase activity for a series of
samples, the samples being characterised into the group type "plasma" or the group type
"infected fluid";
Figure 3A illustrates the difference in results for the two groups of Figure 2 using the
Mann Whitney matched pairs signed test (P=0.002);
Figure 3B illustrates the minor differences in results for the groups wound sourced
sample and blood sourced sample;
Figure 3C illustrates the differences in results between the "infected fluid" group of
Figure 2 and a series of control samples;
Figure 4 shows a Western blot analysis of amylase size distribution showing
degradation/cleavage within an infected environment;
Figure 5 illustrates experimental results showing the concentration difference
between infected wound fluid and plasma for the same individual patient across a series of
patients;
Figure 6 illustrates the concentration difference in the results for the two groups
using the Mann Whitney matched pairs signed test (P<0.0001);
Figure 7a illustrates the concentration difference (wound/plasma) for infected cases,
showing a highly significant difference;
Figure 7b illustrates the concentration difference (wound/plasma) for non-infected
cases, showing no significant difference;
Figure 7c illustrates the concentration difference between experimental cases and
controls, showing a highly significant difference;
Figure 8A provides a Nyquist plot showing the effective response of an
immunosensor, suitable for use in the present invention, t o increasing amylase
concentrations;
Figure 8B shows the resulting EIS calibration curve for the immunosensor of Figure
6A t o increasing amylase concentrations;
Figure 9 provides an EIS calibration curve for the immunosensor of Figure 6A t o
increasing concentrations of amylase in mouse plasma;
Figure 10 provides a Nyquist plot showing the dynamic range detectable when the
sensor was exposed to various human plasma concentrations (9.9 - 1009.9 U/L);
Figure 11 is a Roche Cobas test or recovery, illustrating linearity of recovery for
amylase in plasma and PBS but not linear recovery in infected wound fluid; and
Figure 12 is a schematic a illustration of the construction of the graphene sensor,
including the electropolymerization of polyaniline to the graphene surface.
Amylase
Amylase is a naturally produced enzyme which provides for the breakdown of
components in foodstuffs consumed by humans, other animals, together with some plants
and bacteria. The enzyme acts by catalysing the hydrolysis of the starches present into
sugars. Other enzymes then convert those components t o glucose t o provide an energy
source.
The amylase may be generated by salivary, mammary and lacrimal glands and, in the
case of a particular isoform in the pancreas. It occurs naturally in humans, animals, plants,
fungi and bacteria. More properly this is ct-amylase. a-amylase is also known as 1,4-ct-D-
glucan glucanohydrolase or glycogenase.
In contrast, β-amylase is naturally produced by bacteria, fungi and plant seeds and so
may be present in consumed foodstuffs, β-amylase is also known as 1,4-ct-D-glucan
maltohydrolase. y-amylase is primarily found in yeast and fungi, but is also naturally
produced in some human tissues, particularly within the intestine, y-amylase is also known
as 1,4-ct-D-glucan glucohydrolase.
Amylase is known t o be an aid to diagnosis, for instance through test blood serum,
urine or peritoneal fluid for hyperamylasemia with a view t o informing on acute
inflammation of the pancreas.
More recently, amylase, particularly a-amylase, has been used clinically in pancreatic
enzyme replacement therapy and other treatments.
Detection and quantification of amylase
A variety of sensors or other forms of assay are known which can detect amylase in
samples, however, they function by detecting the activity of amylase. They do not operate
through the detection of concentration, are not capable of the detection of the
concentration levels of amylase typically encountered in medical situations and samples and
do not have the necessary sensitivity to detect very low concentration levels of amylase in
samples. Furthermore, their response is non-linear in some body fluids, with variation in
response to the same activity between body fluids. A sensor offering this combination of
features is not available in the prior art.
Activity based detection can be negatively affected by deviation on pH away from
the 6.7 to 7.0 range optimal for activity and/or due t o temperature and/or due to ionic
composition and/or due t o the composition of the fluid and/or due t o reactions, such as
chelation, reducing activity.
In later sections, a sensor is described which allows for the accurate detection of low
concentrations of amylase in samples.
Initially, however, a use of such a sensor will be described. The use is in the detection
of amylase, more specifically the determination of the concentration of amylase, present in
a sample so as to inform on the presence of infection at a site associated with the source of
the sample. This is a new pattern of amylase distribution, as compared with the four known
patterns; pancreatic, salivary, macroamylasemia and combinations of those three.
The applicant has established that this new pattern of amylase distribution is valid
and applicable through the following testing.
A library of infections was compiled t o represent a variety of patient sex, infection
locations, bacteria identities, dressing type and diagnosis. In the illustrated example of
Figure 1, this was formed of the information from 20 patients. The spread of factors was
used t o investigate whether the new pattern was applicable to a wide variety of different
infections, in terms of organism, site, open and closed wounds, superficial and deep
infections and the like.
Samples were collected from infection sites and tested using a sensor described
further below. Samples were also collected from plasma simultaneously off each patient
and tested in the same manner and using the same sensor. Plasma amylase was used as the
comparator. Whilst amylase is present in plasma, the levels are regulated. Infection causes
enhanced vascular permeability, therefore, large molecules such as amylase are likely t o
sequester t o the site and not be able to drain away because of distorted lymphatics.
Amylase is also likely to be secreted by some bacteria.
Figure 2 shows the amylase activity detected for each of the samples collected.
Some samples were of insufficient volume for testing and are shown as absent data points.
Testing was possible for 14 samples. Figure 2 shows whether these were sample associated
with an infection site or plasma. The site being infected was established to be true through
alternative testing approaches.
Amylase is normally present in human plasma. A substantial difference between the
plasma and the infected fluid sample collected off each of the 20 patients was that amylase
was detected in each and every one of the infected fluid samples. Many of the plasma
samples showed undetectably low concentrations of amylase.
The results of Figure 2 suggest a marked difference in the amylase activity between
plasma samples, where infection is absent, and infection sites, where infection was present.
Figure 3A shows the outcome when Wilcoxon matched pairs signed rank testing is
applied to the results. A separate between the two sample group types is establish with
P=0.002. Figure 3B shows the amylase activity comparison between wound sourced control
samples and blood sourced control samples (p=0.3846). Figure 3C shows the amylase
activity comparison between patients providing infected samples and patients providing
non-infected samples (p<0.0001, n=20). In Figure 2, 3A, 3B and 3C an activity difference is
under consideration.
Figure 4 shows the results from Western blot analysis of amylase size (kDa)
distribution from a variety of samples and is indicative of cleavage/degradation of the
amylase occurring.
Figure 5 considers the concentration difference for pairs of results, one of the pair
being a plasma sample and the other being an infected site sample taken from the same
patient. 20 sample pairs were considered in this case consistent with the patients in the
library of Figure 1. Figure 5 shows that the difference in concentration between the two
samples from the same patient is significant in each and every case tested; 100% increase in
concentration in the infected sample in many cases. The sensor showed excellent sensitivity
(98%) and high specificity (90%) with respect t o infection in the measurement results
generated. Sensitivity being the ability to correctly identify those with the infection (true
positive rate); specificity being the ability to test correctly t o identify those without the
infection (true negative rate).
In Figure 6 the outcome from the application of Mann Whitney matched-pairs
signed rank testing is seen. The separation between the two sample types is clearly
established with P<0.0001.
Figures 7a, 7b and 7c show the outcome from the application of Mann Whitney
matched pair signed rank testing. With Figure 7a being infected cases, Figure 7b being non-
infected cases and Figure 7c controls.
The results show that the difference in amylase between a site of interest and
intravascular fluid (defined above) can be used t o determine the presence of infection, or its
likelihood, at the site of interest. If the activity difference (site of interest versus
intravascular fluid) is considered, the distinction is statistically significant. If the
concentration is considered, then the distinction is highly statistically significant. The
amylase difference between infected and non-infected sites is highly sensitive t o the
presence of infection.
The experimental results show that the detection of activity and more usefully
concentration difference reveals whether or not infection is present at the site. This
information could be used to direct subsequent and further investigations. For instance, a
determination as t o the nature of the infection could be sought, for instance by microbial
culture, microscopy, biochemical testing, molecular testing, immunoglobulin binding t o
amylase or others. This information on the infection can be combined with information on
the incident or procedure leading t o the wound and then used by a medical practitioner t o
diagnose a medical condition and the form of treatment appropriate.
A significant benefit of being able t o establish that infection is present at the wound
site and needs treatment is that no treatment need be given where no infection is
established to be present. At the moment, clinical practice errs on the side of caution and so
antibiotics, as infection treatment, are administered in most situations. This represents
unnecessary antibiotic use and so contributes t o wasted costs and, more significantly,
increased build-up of resistance t o antibiotics.
The applicant has established that this new pattern of amylase distribution is valid
and applicable for detecting infection at sites.
In terms of the mechanism by which amylase distribution arises at the site of
infection, then there are various possibilities. Amylase which is occurring naturally in the
body and distributed throughout the body could be caused to collect at the infection site.
One way this could be caused t o happen is through enhanced vascular permeability,
and reduced lymphatic clearance: (the so-called enhanced permeability and retention
effect). Histamine release has been reported t o stimulate amylase secretion and increase
vascular permeability, thereby augmenting the EPR effect.
However, the significant, selective and specific sequestration of amylase to a focus of
infection reported herein is to a greater extent than seems explained by the EPR effect.
Potentially, the effect is suggested to be due to invasive infection being accompanied
by constant bradykinin production which amplifies the limited enhanced vascular
permeability observed in non-specific infection, such as that produced in a surgical insult.
The applicant's view is that the most plausible mechanism is that once in this
pharmacokinetic compartment that amylase complexes immunoglobins, resulting in
entrapment. The applicant references this as Microbe-Associated Large Molecule Trapping
and Aggregation phenomenon, MaLTA phenomenon.
Finally, certain classes of micro-organisms secrete amylase themselves, for example
C. perfringens (a cause of gas gangrene), C. tetanii (tetanus), C. difficile (hospital acquired
pseudomembranous colitis) and B. cereus (food poisoning) are all within the Bacillus and
Clostridium genus and those are known t o be capable of prolific amylase secretion and so
may cause the observed increased amylase levels around infected sites, potentially several
orders of magnitude higher.
The mechanism by which the amylase sequesters t o the infection site is not material
to the invention. The invention has demonstrated that this effect is medically indicative of
infection and makes use of it, irrespective of the mechanism of sequestration, t o produce
clinically useful results.
Initial results show that the use of amylase as a biomarker of infection at sites is a
robust method and is capable of dealing with the likely variations in pH, calcium and
proteolytic activity to be expected at such sites. The use of amylase as a biomarker of
infection also seems capable of successful operation in the context of a wide variety of
different dressings, including Negative Pressure Wound Therapy, antibiotic treatment, site
and anatomical plane, together with severity of infection.
The description above makes it clear that the method and the sensors used are
capable of detecting infection at a site. As an extension of that, it is possible t o link the
concentration level of amylase observed t o the level of infection; higher levels of infection
generating higher concentrations of amylase at the site and in the samples.
In a further extension of that method, it is possible to establish the form of the
infection which is present. One possibility in this respect is that the body will generate
antibodies specific to the infection caused by the specific bacteria which is the cause of the
infection. These antibodies have been observed to form complexes of immunoglobulins and
amylase. This means that the antibodies specific to the infection will be in the sample taken
and so could be identified in parallel with the detection of the amylase concentration.
Amylase has been observed to have the capacity t o complex with immunoglobulins.
This means that the antibodies specific t o the infection will be in the sample taken and so
could be identified in parallel with the detection of amylase. In one such embodiment, this
could be done via multiplex sensing.
The interaction between the at least a part of the sample and the sensor occurs
without the need for the human or animal body from which the sample arises being present
and/or without any interaction between the device and the human or animal body which is
the source of the sample. The method is provided outside the normal biological context of
the sample. The method is performed outside of the human or animal body and distant
therefrom. The method is provided in-vitro by the device and the sensor. The invention
provides an in vitro diagnostic device. The invention provides in vitro testing for the marker.
Other Applications of the Detection
It has been suggested that pharmaceutical compounds can be introduced to a body
in an inactive form, with the inactive form arising because the pharmaceutical compound is
linked in some way t o another compound which inactivates it. Whilst the inactive form
would be administered to the body as a whole, for instance through injection, it could be
activated at the site of interest by the activity of the amylase at that site. Thus the inactive
form could be designed such that amylase causes it t o breakdown or amylase catalyses the
breakdown such that the active compound is rendered pharmaceutically active. The analysis
of the invention could be used t o establish that there is sufficient amylase, by activity
and/or concentration, at the site t o cause the activation and/or to impact upon the dosage
given or delivery method used because of the level of amylase present at the desired
release location.
In a similar manner, the transportation of the pharmaceutical compound as part of a
combination with amylase (described further in the next section), could be inspected by the
analysis of the present invention t o detect for the amylase following breakdown and hence
the release of the active compound. Verification of the release would be provided.
Using Amylase as a Transportation Mechanism for Pharmaceutical Compounds
Whilst it has been suggested that amylase which is already naturally occurring at a
site could be used t o turn an inactive form including a pharmaceutical compound into an
active form, potentially by releasing the pharmaceutical compound, the applicant has
realised that amylase itself could be used as a transportation mechanism.
When a site transitions from a non-infected t o an infected site, amylase moves to
and accumulates at the site, as established by the applicant above. If that amylase or some
portion of it was linked to a pharmaceutical compound, then the pharmaceutical compound
would be preferentially transported t o the infection site. The same could apply to other
sites at which amylase accumulates or is drawn in other disease situations. Thus amylase
offers a targeted delivery system in such cases.
Once at the site, release of the pharmaceutical compound would be triggered.
A variety of constructs could be used. The amylase could be linked directly t o the
pharmaceutical compound. The amylase could be linked to an intermediary which is in turn
linked to the pharmaceutical compound.
The linking could be provided using a number of bio-conjugate techniques and
chemistries , including but not limited to zero-length cross-linkers homo-bifunctional or
heterobifunctional spacers which can be non-biodegradable (such as polyethylglycol) or
biodegradable; homogenous or heterogenous.
The pharmaceutical compound could be an antibiotic, for instance for treating
infection at the site where the amylase accumulates. Other pharmaceuticals could be
analgesics, growth factors etc.
Sensor
The sensor employed in the sample testing described above can be generally
categorised as a graphene label free immunosensor. In more detail it is a highly sensitive a-
amylase immunosensor platform, produced via in situ electropolymerization of aniline onto
a graphene support. Electropolymerization has a material role in improving the sensitivity in
detection for amylase and providing lower limits of quantification. This is a significant
difference when compared with the assembly of other sensors developed for other purposes,
such as those disclosed in WO2015/001286. At the same time, excellent reproducibility and
stability in detection are provided, as shown in Figures 8, 9, 10 and 11. Covalently binding an
a-amylase specific antibody t o a polyaniline (PANI) layer and controlling device assembly
using electrochemical impedance spectroscopy (EIS) provides a highly linear response against
a-amylase concentration.
To improve reproducibility of absolute readings using the sensor, when such a
graphene sensor is applied, the invention suggests the use of a double sensor where
simultaneous or near simultaneous readings are taken, for instance with respect t o the
plasma versus fluid of interest. This results in a relative scale of the magnitude of the
difference, and hence a solution for the problem.
Further detail on the testing of the sensor for this purpose and further detailed
information on the construction of the sensor is provided below.
The type of sensor used in the testing of the invention is beneficial when compared
with most existing devices. In most cases, such devices are far from being bedside
monitoring devices for ct-amylase detection. Current a-amylase assays in clinical use are
laboratory based, utilize analytical equipment with a large footprint, have an appreciable
turnaround time (TAT), measure activity rather than concentration, and are susceptible to
hemolysis and inactivation. These substantial limitations restrict further expansion of a-
amylase based diagnostics and theranostics into viable clinical practice. No use of the
detection of amylase and particularly a-amylase to indicate infection has been made before.
Demonstrations of Sensor Performance
The performance of the sensor was explored in various ways, including:
determination of amylase in a blood plasma mimic; determination of amylase in mouse
plasma; and determination of amylase in human plasma.
Blood Plasma Mimic
The sensor was tested for its ability t o measure amylase concentrations in a phosphate
buffered solution that was used as a blood plasma mimic. Increasing amylase concentrations,
from 1 t o 500U/L, which covers the clinically relevant range of amylase levels in the human
body, were applied t o individual sensors. Both Nyquist plots (Figure 8A) and the resulting EIS
calibration curve (Figure 8B) clearly demonstrate the effective response of the immunosensor
to increasing amylase concentrations.
The diameter of the semicircle increased with increasing amylase concentrations
demonstrating an increased resistance as a result of increased analyte concentration at the
sensor surface. In general, the change in the semicircle diameter is a result of the change in
the interfacial charge transfer resistance (Ret); that is, the resistance corresponding to the
carrier transfer from the modified electrode t o the ferricyanide in the solution. Thus, the
observed diameter increase is explained as the adsorption of plasma onto anti-alpha amylase
following an antigen-antibody reaction, where the adsorption of plasma effectively blocks
the [Fe(CN)6] 4 leading t o an increase of Ret. The Ret in the Nyquist plot increased linearly
with the amylase concentrations. This is as expected because protein structures bound t o the
surface of an electrode typically act as barriers t o electric transfer. The average slope of the
Ret versus log [amylase, U/L] was 0.348 KQ/[amylase, U/L] with an R2 coefficient of
determination of 0.93. The limit of detection (LOD) was 0.0025U/L. This was as expected as
protein structures bound t o the surface of an electrode typically act as barriers to electric
transfer.
Mouse Plasma
In order to demonstrate that the sensor function was effective when exposed to a
more complex biological fluid, mouse plasma containing known quantities of amylase were
used, a-amylase concentrations were measured in un-spiked and plasma samples with
purified human- a-amylase. The linear response ranged from 1 t o 1000 U/L and the average
slope was of 0.472 KQ[amylase, U/L]. The EIS calibration curve of the immunosensor in
response to increasing concentrations of amylase in mouse plasma showed no adverse effect
on sensor performance in the presence of a more complex fluid compared t o the PBS (Figure
9).
Human Plasma
To provide proof of function for a clinically useful device, human plasma samples
obtained from a patient suffering with clinical infection were analyzed. By spiking the human
plasma with known concentrations of amylase we were able to determine the effectiveness
and LOD of the sensor at physiologically relevant analyte concentrations.
Nyquist plots (Figure 10) of EIS spectra show the dynamic range detectable when the
sensor was exposed to various human plasma concentrations (9.9 - 1009.9 U/L).
Overall, the sensor was demonstrated t o offer highly sensitive detection and a
remarkably wide limit of quantification (0.025-1000 IU/L) compared to α-amylase assays in
current clinical use.
In addition, the sensor had a maximum interval to obtain a result of 300 seconds. This
compares very well with existing devices in clinical practice, where, despite turnaround times
(TAT) being a key indicator of laboratory performance, the current TAT for clinical assays is
around 45 minutes.
Moreover haemolysis, sample inactivation, and the presence of contaminants
interfering with colorimetric assays commonly lead t o assay failure with current clinical assay
systems. Since the system described in this document is label-free, and does not require
either colorimetric change, it is reasonable to support the notion that the new technology will
not be affected such factors.
Finally, it is worth noting that the results indicate a three-log fold expansion in the
lower limit of quantification when compared t o current clinical assay systems. This is of
interest t o forensic medicine where detection of amylase can lead t o a DNA profile from
saliva, semen or vaginal secretions.
Sensor Construction
Electrochemical impedance spectroscopy (EIS) enables detection and signal output
due t o its ability t o measure subtle changes in the electrochemical properties of materials at
their interface with conducting electrodes. Gold, zinc oxide, iron oxide, and carbon are the
main substrates that are being developed for use in such sensors, but carbon nanostructures,
and graphene, are alternatives to gold as electrode substrates.
Graphene is of particular interest as a biosensor platform due t o intrinsic properties
such as its large surface area, high electrical conductivity and biocompatibility. Graphene
based devices have been developed that can measure minute changes in analyte
concentration levels. Composed of sp2 carbon, graphene is chemically unsaturated.
Intrinsically, it can undergo covalent addition to change the carbons from sp2 t o sp3 following
hybridization, however, carbon atoms in the graphene basal plane are protected by their π -
conjugation system, the motion of which is constrained by surrounding carbon atoms.
Therefore, basal plane covalent addition usually encounters large energy barriers, and
reactive chemical groups, such as atomic hydrogen, fluorine, and pre-cursors of other
chemical radicals, are usually needed as reactants. The controlled functional association of
biomolecules with graphene is therefore key to developing any high throughput biosensor
platform.
Figure 12 provides a schematic illustration of the construction sequence for a suitable
sensor.
Polyaniline (PANI) is a conductive polymer and is used as an additive transducer layer
in the sensor t o avoid the introduction of graphene surface defects. In addition the use of
PANI improves antibody attachment t o sensor electrodes while preserving optimal electrical
characteristics. In addition, PANI has excellent acid/base sensitivity, a huge range of tunable
conductivity, redox sensitivity, environmental stability, short reversible response times, and
is easily synthesized and functionalized.
The sensor of this document is an a-amylase specific immunosensor, using a
combination of electro-polymerization of PANI on a graphene support and subsequent
antibody binding to the polymer film.
The selection of electropolymerization has a material role in improving the sensitivity
in detection for amylase and providing lower limits of quantification. At the same time,
excellent reproducibility and stability in detection are provided, as shown in Figures 8, 9, 10
and 11.
The biosensor platform enables fully quantitative analysis of analyte concentrations in
a simulated biological sample and in human plasma. The device displays a linear response t o
increasing a-amylase concentration between 1 and 1000 International Units/L (IU/L), and a
LOD of 0.025 U/L. This increased sensitivity arises because of electrochemical deposition.
In construction, a screen-printed graphene electrode was functionalized via
polymerization with a thin film of polyaniline to provide amine groups on the graphene/ PANI.
The PANI film was formed by coating the electrode in a solution of aniline and subsequent
electropolymerization to form a conductive polymer layer over the graphene support,
enabling the transport of electron carriers t o the graphene.
Having deposited polyaniline, the sensor was then functionalized through covalently
linking a α-amylase antibody to the PANI layer. A carbodiimide crosslinker chemistry
EDAC/NHS was used for the specific activation of the -COOH terminated amino acid chains in
the antibody. This forms a highly reactive O-Acylisourea intermediate that rapidly reacts with
NHS t o produce a stable succinimydyl ester. This ester then undergoes a nucleophilic
substitution reaction with the amine groups on the PANI, leading to the formation of an
orientated antibody grafted PANI layer. Due t o exposure to the EDAC/NHS reagents, it is
possible that each of -COOH groups at the antibody may have been activated. It is not possible
therefore to ensure exclusive antibody binding through the Fc region, only that orientation
via the Fc region is significantly higher than with random antibody adsorption. Bovine serum
albumin (BSA) was then added to the sensor surface randomly, and serves t o prevent any
non-specific interactions with the sensor surface thereby eliminating the possibility of the
sensor generating any non-specific background signal.
Whilst the above is an example of a suitable sensor, other suitable sensors capable of
detecting amylase activity and more preferably concentration, can be used. These include the
sensors disclosed in:
Federal Drug Agency (FDA) 510(k) substantial equivalence determination decision
summary device only templat.
http://www.accessdata.fda.gov/cdrh docs/reviews/K040534.pdf; (b) Bowling, J. L ;
Katayev, A., An evaluation of the Roche Cobas c 111. Lab Medicine 2010, 41 (7), 398-
402.
Together with the sensors described in the following table and which are available in clincial
practice. AMP = Amperometric, EIS = Electrochemical Impedance Spectroscopy, FAU= Fungal Amylase Unit,
FIA = Flow Injection Analysis, KNU = kilo Novo unit, LOD = Limit of Detection, LR = Linear Range, nkat =
nanokatals
Assay Design Detection Limits of detection Specificity Ref.
Sequential Process Technique
Flow system using a a-glucosidase LOD: 2nkat/mL Any a- [145]
peroxide electrode and converts maltose t o (0.117.64 units/mL) amylase
enzyme membrane with a-D-glucose. when reaction time
c
o
glucose oxidase, c - Mutarotase 5 min
glucosidase and converts a-D- 0.5 nkat/mL
E optionally mutarotase glucose t o β -D- (0.02941 units/mL)
cross-linked by gelatin- glucose which is when reaction time





its/mL Any a-Screen-printed α-glucosidase AMP LOD: 5 un [146]
0 electrodes with converts maltose t o amylase
immobilized a- a-D-glucose. LR: 5-250 units/mL
glucosidase, glucose Mutarotase
oxidase and mutarotase converts a-D-
modified with Prussian glucose t o β -D-
Blue glucose which is
determined via
glucose oxidase
Flow-injection device α-glucosidase AMP LOD: Any a- [147]
using maltopentaose as converts maltose t o amylase
substrate, a-glucosidase 5-d-glucose. LR: 0-30 units/mL
immobilised on pre- Glucose oxidase
activated membrane. coverts 5-d-glucose
Glucose oxidase t o gluconic acid and
immobilized on hydrogen peroxide
electrode which is measured
Spectrophotometric flow Amylose incubated LOD: 0.0048 FAU Any a- [148]
injection measuring with sample to LR: 0.005-0.06 FAU amylase
brick red complex produce maltose.
formation at 540nm 3,5 dinitrosalicylic-
acid and maltose
boiled
Use of portable personal Sample, a- LOD: 20 U/L Any a- [149]
glucose meter glucosidase and amylase
maltopentaose LR: 2.2-27.8 mM
incubated 15 min at
37°C.
Flat-chip micro analytical Maltose Electroche LR: 0-190 kU/L Any - [147]
dges
sensor used as part of a phosphorylase mical and amylase
Micro-Electro- phosphorylates Lateral
Mechanical Systems. maltose. Glucose flow
Pre-column and flat- oxidase converts
enzyme electrode phosphorylated
incorporated into a flow maltose to gluconic
cell where maltose acid and hydrogen
phosphorylase, glucose peroxide which is
oxidase and peroxidase measured
immobilised
Colorimetric assay Disposable test AMP LR: 10-230 U/mL Any - [150]
biosensor system using strip placed under amylase
Gal-G2-CNP, tongue (25 µ Ι).
chromogenic substrate Once strip inserted
for a-amylase. CNP is a into reader and
yellow product once saliva moved onto
hydrolysed which can be the reagent paper.
measured The entire test
photometrically at takes roughly 30
430nm. sec.
Flow injection Sample degradation FIA LOD: 60 NU/mL Any c - [151]
spectrophotometric of complexes LR: 0.25-5.0 amylase
analysis based on starch- measured in flow KNU/mL
iodine complexes channel
Immobilized layer of Sample placed on LR: 75-125 U/mL Any c - [152]
starch gel on thick-film starch gel amylase
c magneto elastic sensor
and presence of -
amylase alters the
resonance frequency
Spectrofluorimetric Sample incubated FIA LOD: 5.7 x 10 Any c - [153]
using the quenching of with starch in flow mol/L amylase
o luminescence intensity channels
+-)» (634nm) of nano CdS LR: 4.8 x 10 1 - 1.2
doped in sol-gel of x 10 mol/L
different concentrations
of maltose
Glycogen/amylopectin Sample incubated EIS Any a- [154]
spin-coated on gold with film amylase
coated quartz crystals







Degradation of starch- Sample incubated LOD: 1.944 mU Any - [155]
triiodide measured using with starch- amylase
platinum redox sensor triiodide LR: 0-0.54 U
for direct potentiometric
determination
Glucose oxidase-based LOD: Any - [156]
biosensor measuring the amylase






Layer of salivary The electroactive LOD: 1.57 pg mL Human [113
antibody on Au- was oxidized or LR: 0.003-0.016 salivary
p electrode and reduced depending ng/mL amylase
c interactions monitored on concentration of
O by an electroactive salivary a-amylase
indicator (K3Fe(CN)6). present
CLAIMS
1. A method of indicating the presence of a bacterial infection in a biological sample by
investigating a marker for infection, the method comprising:
a. providing a device, the device including a biosensor, an interaction arising
between the biosensor and the marker when the marker is present in the
biological sample;
b. contacting at least a part of the biological sample with the biosensor of the
device;
c. analysing the at least a part of the biological sample with respect to the marker
by detecting for the interaction between the biosensor and the marker;
d. indicating a characteristic of the marker using the device, the characteristic
being the presence or absence of the marker;
e. wherein the marker is an enzyme.
2. A method according to claim 1, wherein the enzyme is amylase.
3. A method according to claim 1 or claim 2 wherein, the method is a method of
diagnosing infection.
4. A method according to any preceding claim, wherein the method is a method of
analysing for elevated marker levels at a site
5. A method according to claim 4, wherein the elevated levels compared with marker
levels at another location of the same patient, such as the blood.
6. A method according to any preceding claim, wherein the method is a method of
quantifying the amount of the marker in the at least a part of the biological sample.
7. A method according to any preceding claim, wherein the method is a method of
quantifying the concentration of the marker and/or the activity of the marker relative
to the concentration and/or activity of the marker in a reference sample.
8. A method according to claim 7, wherein the reference sample is another biological
sample taken from the same source, for instance the same human or animal.
9. A method according to claim 7 or claim 8, wherein the reference sample is taken from
another site on the source to the site being analysed for instance for infection.
10. A method according to any preceding claim in which a site is analyised and the site is
one or more of: on the exterior of a body; the interior to a body; a surgical site; a
disease site; a pathology site; an infection site; an injury site; a burn site.
11. A method according to any preceding claim in which the infection is a bacterial
infection.
12. A method according to any preceding claim in which the device includes the sensor
together with one or more or all of: a power source; control electronics; a computer
processor; computer memory; a user interface; a user viewable display; a signal
output connection; a signal input connection.
13. A method according to any preceding claim in which the sensor is: screen printed on to
a part of the device; and/or is a graphene based sensor; and/or includes an amylase
antibody and/or includes electropolymerization of a component of the sensor.
14. A method according to claim 13, in which the sensor includes an a-amylase specific
antibody.
15. A method according to any preceding claim in which the sensor is an electrochemical
impedance spectroscopy sensor.
16. A method according to any preceding claim in which the sensor has a linear response
against a-amylase concentration and/or detects concentrations of the marker as low as
100 International Units/L (IU/L).
17. A method according to any preceding claim in which the sensor detects concentrations
of the marker as low as 1 International Units/L (IU/L).
18. A method according to any preceding claim in which the sensors has a limit of detection
as low as 0.025 U/L.
19. A method according to any preceding claim in which the characteristic is one or more
of: the presence of the marker; the absence of the marker; the level of the marker;
quantity of the marker; the activity of the marker; the concentration of the marker.
20. A method according to any preceding claim in which the characteristic is one or more
of: the presence of infection due to the presence of the marker; the absence of infection
due to the absence of the marker; the presence of infection due to the level of the
marker; the absence of infection due to the level of the marker; the presence of infection
due to the quantity of the marker; the absence of infection due to the quantity of the
marker; the presence of infection due to the activity of the marker; the absence of
infection due to the quantity of the marker; the presence of infection due to the
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